Efficacy, safety, and tolerability of overnight switching from immediate- to once daily extended-release pramipexole in early Parkinson's disease

2010 ◽  
Vol 25 (14) ◽  
pp. 2326-2332 ◽  
Author(s):  
Olivier Rascol ◽  
Paolo Barone ◽  
Robert A. Hauser ◽  
Yoshikuni Mizuno ◽  
Werner Poewe ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Extended Release ◽  
Once Daily ◽  
Early Parkinson’S Disease

Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease

2010 ◽  
Vol 25 (15) ◽  
pp. 2542-2549 ◽  
Author(s):  
Robert A. Hauser ◽  
Anthony H.V. Schapira ◽  
Olivier Rascol ◽  
Paolo Barone ◽  
Yoshikuni Mizuno ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Extended Release ◽  
Double Blind ◽  
Once Daily ◽  
Early Parkinson’S Disease

GOCOVRI® (amantadine) extended-release capsules in Parkinson's disease

2021 ◽  
Author(s):  
Thomas Müller
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Extended Release ◽  
Motor Behavior ◽  
Brain Delivery ◽  
Antiviral Compound ◽  
Once Daily ◽  
Beneficial Effects ◽  
Central Monoamine ◽  
Preventive Effects

Amantadine is an old, antiviral compound, which moderately improves motor behavior in Parkinson's disease. Its current resurgence results from an innovative, delayed uptake and extended release amantadine hydrochloride capsule, given at bedtime once daily. It is the only approved compound for reduction of involuntary movements, so called dyskinesia, in fluctuating orally levodopa treated patients. It additionally ameliorates ‘off’-intervals characterized by impaired motor behavior. These beneficial effects result from higher and more continuous brain delivery of amantadine. Future clinical research is warranted on preventive effects of this amantadine capsule combined with enzyme blockers of central monoamine oxidase B and peripheral catechol-O-methyltransferase on motor complications in orally levodopa treated patients, as all these pharmacological principles support the concept of continuous dopamine substitution.

scholarly journals Pramipexole and its Extended Release Formulation for Parkinson's Disease

2011 ◽  
Vol 3 ◽  
pp. JCNSD.S5210 ◽  
Author(s):  
Paul S. Fishman
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Extended Release ◽  
Immediate Release ◽  
Motor Fluctuations ◽  
Release Formulation ◽  
Extended Release Formulation ◽  
Release Preparation ◽  
Early Parkinson’S Disease ◽  
Release Form

Pramipexole has been a widely used dopamine agonist for the last decade. Recently an extended release formulation of pramipexole has been introduced as both monotherapy for patients with early Parkinson's disease as well as for patients with more advanced disease, as an adjunct to L-DOPA. Along with the enhanced patient compliance seen with once a day dosing, there are other potential advantages of extended release preparations of dopamine agonists. Patients initiated on pramipexole have a lower incidence of developing motor fluctuations including dyskinesia than those initiated on L-DOPA. Pramipexole requires a prolonged dose titration compared to L-DOPA, and generally does not have the efficacy of L-DOPA. The extended release form of pramipexole shows comparable mean and peak serum levels with once a day dosing as seen with three times a day dosing of the immediate release preparation. The extended release preparation has been studied in randomized multicenter clinical trial against both placebo and the immediate release preparation in the setting of early Parkinson's disease as monotherapy and in more advanced patients with motor fluctuations on L-DOPA. In both settings the extended release preparation was superior to placebo and comparable to the immediate release form in efficacy with a similar side effect profile including nausea, sleepiness, leg edema, dyskinesias, hallucinations and impulse control disorders.

scholarly journals Twice-Daily versus Once-Daily Pramipexole Extended Release Dosage Regimens in Parkinson’s Disease

2017 ◽  
Vol 2017 ◽  
pp. 1-8
Author(s):  
Ji Young Yun ◽  
Young Eun Kim ◽  
Hui-Jun Yang ◽  
Han-Joon Kim ◽  
Beomseok Jeon
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Extended Release ◽  
Daily Regimen ◽  
Open Label ◽  
Multiple Dosing ◽  
Once Daily ◽  
Open Label Study ◽  
Dopamine Agonist Therapy ◽  
Second Period

This open-label study aimed to compare once-daily and twice-daily pramipexole extended release (PER) treatment in Parkinson’s disease (PD). PD patients on dopamine agonist therapy, but with unsatisfactory control, were enrolled. Existing agonist doses were switched into equivalent PER doses. Subjects were consecutively enrolled into either once-daily-first or twice-daily-first groups and received the prescribed amount in one or two, respectively, daily doses for 8 weeks. For the second period, subjects switched regimens in a crossover manner. The forty-four patients completed a questionnaire requesting preference during their last visit. We measured the UPDRS-III, Hoehn and Yahr stages (H&Y) in medication-on state, Parkinson’s disease sleep scale (PDSS), and Epworth Sleepiness Scale. Eighteen patients preferred a twice-daily regimen, 12 preferred a once-daily regimen, and 14 had no preference. After the trial, 14 subjects wanted to be on a once-daily regimen, 25 chose a twice-daily regimen, and 5 wanted to maintain the prestudy regimen. Main reasons for choosing the twice-daily regimen were decreased off-duration, more tolerable off-symptoms, and psychological stability. The mean UPDRS-III, H&Y, and PDSS were not different. Daytime sleepiness was significantly high in the once-daily regimen, whereas nocturnal hallucinations were more common in the twice-daily. Multiple dosing should be considered if once-daily dosing is unsatisfactory. This study is registered asNCT01515774at ClinicalTrials.gov.

Sign in / Sign up

Export Citation Format

Share Document